This story has been updated with additional information on MDxHealth's MGMT glioblastoma test.
A new study provides further support for MDxHealth's PredictMDx brain cancer test, which predicts which patients will respond to the alkylating chemotherapy temozolomide.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.